Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Shields BM. et al, (2022), Nat Med
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842
Endpoints and estimands: understanding trials of weight-loss drugs.
Adler AI., (2022), Nat Med, 28, 2005 - 2006
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
Samsky MD. et al, (2021), Atherosclerosis, 338, 1 - 6